BI 764198が巣状分節性糸球体硬化症（FSGS）と呼ばれる腎臓疾患の成人および青年に効果があるかどうかを調べる研究

基本情報

NCT ID

NCT07220083

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

286

治験依頼者名

Boehringer Ingelheim

概要

This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS. Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine. Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS. Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

対象疾患

介入

依頼者（Sponsor）

実施施設 (15)